Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.

Next Previous
Trial Profile

Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegipanermin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker; Proof of concept
  • Sponsors INmune Bio

    • Most Recent Events

    • 17 Oct 2023 According to an INmune Bio media release, new biomarker and feasibility data will be presented at the 16th annual Clinical Trial in Alzheimer's Disease (CTAD) 2023.
    • 17 Oct 2023 Results presented in an INmune Bio Media Release.
    • 20 Jul 2023 Results of post hoc analysis of Clinical and biomarker correlates of region-specific diffusion MRI metrics in a short-term, presented at the Alzheimer's Association International Conference 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top